ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SRRK Scholar Rock Holdings Corporation

9.21
0.00 (0.00%)
16 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Scholar Rock Holdings Corporation NASDAQ:SRRK NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.21 8.80 9.20 0 01:00:00

Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference

05/08/2021 9:01pm

Business Wire


Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart


From Jul 2021 to Jul 2024

Click Here for more Scholar Rock Charts.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th, 2021 at 9:10 a.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit https://scholarrock.com/ or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Scholar Rock Contact: Investors/Media Catherine Hu chu@scholarrock.com

Media Contact: Ariane Lovell Finn Partners ariane.lovell@finnpartners.com 917-565-2204

1 Year Scholar Rock Chart

1 Year Scholar Rock Chart

1 Month Scholar Rock Chart

1 Month Scholar Rock Chart